ArticlePediatric research2026
Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric cancer survivors are at risk of short- and long-term complications from cancer treatment, including acute kidney injury (AKI) and chronic kidney disease (CKD). Our aims were to assess AKI incidence, examine potential risk factors for AKI during pediatric central nervous system (CNS) tumor treatment, and evaluate for kidney function impairment in survivorship. We hypothesized that any chemotherapy exposure and burden would be associated with higher risk of AKI.
methodsWe reviewed medical records of pediatric CNS tumor survivors treated between 2007 and 2015. The primary outcome was AKI frequency during cancer treatment. Secondary outcomes were severe AKI (sAKI) occurrence during treatment and presence of chronic kidney injury markers (estimated glomerular filtration rate <90 ml/min/1.73m
results123 patients received CNS tumor treatment during the study period. Out of 41 patients with sufficient serum creatinine (SCr) data available to assess for AKI, 12 had AKI. Chemotherapy exposure was associated with a higher AKI incidence. Fifty-six percent of patients had chronic kidney impairment during survivorship.
conclusionAcute and chronic kidney injury are common in patients with CNS tumors, but detection is limited by heterogeneity of tumor type and adequate SCr availability. IMPACT: Acute kidney injury (AKI) is common during treatment of pediatric tumors of the central nervous system. AKI detection is limited by low availability of adequate serum creatinine measurements in high-risk patients. This longitudinal cohort links AKI presence during cancer treatment with chronic kidney disease during survivorship. Identifying AKI as a CKD risk factor can inform preventive measures and improve monitoring strategies.
Identifiers
42595820What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.